DTS-201

• Description :

  DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin (HY-15142A) . DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer[1].

• UNSPSC :

  12352005

• Target :

  Aminopeptidase; Peptide-Drug Conjugates (PDCs)

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  OC(CCC(NCCC(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@H]([C@H](O)[C@H](C)O1)C[C@]1([H])O[C@@H]2C3=C(C[C@](C(CO)=O)(O)C2)C(O)=C4C(C(C5=C(OC)C=CC=C5C4=O)=O)=C3O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C49H65N5O18

• Molecular Weight :

  1012.06

• References & Citations :

  [1]Ravel D, et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008, 14 (4), 1258–1265.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [274912-87-7]